Clinical Trial

Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk Individuals

Study acronym: LEAH
Recruiting
View on ClinicalTrials.gov →
Summary
LEAH is a prospective, observational, single-centre, non-randomised, open-label study of people at increased risk of cancer or malignant disease. The main objective of LEAH is to evaluate and compare the sensitivity of different tests on body fluids to detect cancers that will occur within 3 years of inclusion in the study, in a cohort of individuals identified as being at increased risk of cancer.
Protocol Amendment History 1 change
critical Recruitment opened 2026-03-31
Trial Details
NCT Number NCT06907095
Lead Sponsor Gustave Roussy, Cancer Campus, Grand Paris
Conditions Risk of Breast Cancer, Risk of Gynaecological Cancer, Risk of Colorectal Cancer, Risk of Upper Gastrointestinal Cancers, Risk of Hepatic Cancers, Risk of Lung Cancer, Risk of Skin Cancers Except Basal-cell Carcinomas, Risk of Head and Neck Cancers +9 more
Enrollment 5,909 participants
Start Date 2026-03-16
Primary Completion 2030-06 (estimated)
Study Completion 2030-06 (estimated)
Updated on ClinicalTrials.gov 2026-03-30